The FDA granted approval for the biologics license application, or BLA, submitted by BeiGene U.S.A. for Tevimbra injection, for intravenous use, according to a letter posted to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
- BeiGene announces first doses of Brukinsa administered
- BeiGene announces FDA accelerated approval of BRUKINSA
- BeiGene announces new efficacy analysis comparing Brukinsa vs. Acalabrutinib
- BeiGene price target lowered to $345 from $350 at Guggenheim
- BeiGene price target raised to $235 from $224 at TD Cowen
